While 36 US states and four territories permit medical cannabis use, much current evidence is anecdotal and lacks the robustness of randomized clinical trials, leading to inconsistent findings. This grant, offered by a national health initiative, aims to address this critical gap by establishing a comprehensive registry. Its purpose is to systematically gather robust data on medicinal cannabis products, including reasons for, timing of, and health outcomes of their use. A key objective is to understand their impact on other medication use, such as opioids. The initiative also involves a coordinating center responsible for archiving, analyzing, and disseminating this vital information to optimize patient benefits and mitigate potential harms.
Opportunity ID: 341134
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-23-011 |
| Funding Opportunity Title: | Registry of Medical Cannabis Use and Health Outcomes (UM1 – Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 14, 2022 |
| Last Updated Date: | Jun 14, 2022 |
| Original Closing Date for Applications: | Nov 15, 2022 |
| Current Closing Date for Applications: | Nov 15, 2022 |
| Archive Date: | Dec 21, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Private institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) For profit organizations other than small businesses Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | oAs of May 18, 2021, 36 US states and four territories allow for the medical use of cannabis products. Current evidence from global database registries and other patient reported outcomes incorporate information from thousands of patients, but much of the evidence is based on anecdotal reports rather than possessing the robustness of randomized clinical trials, and these different types of sources are not always in agreement. As many patients are already using cannabis products for medicinal applications, it is important to identify the evidence that exists and as it evolves, and to harmonize and coordinate this information to maximize the potential benefits to patients while minimizing harmful effects. The goal of this cannabis registry is to gather information regarding medicinal cannabis products used as well as timing of, reasons for, and outcomes of use and impacts on other non-cannabis medication (e.g., opioids) use. This coordinating center will also lead efforts in archiving and analyzing these data, as well as disseminating their findings. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-011.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00274993 | Oct 15, 2022 | Nov 15, 2022 | View |
Package 1
Mandatory forms
341134 RR_SF424_5_0-5.0.pdf
341134 PHS398_CoverPageSupplement_5_0-5.0.pdf
341134 RR_OtherProjectInfo_1_4-1.4.pdf
341134 PerformanceSite_4_0-4.0.pdf
341134 RR_KeyPersonExpanded_4_0-4.0.pdf
341134 RR_Budget_3_0-3.0.pdf
341134 PHS398_ResearchPlan_4_0-4.0.pdf
341134 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
341134 RR_SubawardBudget30_3_0-3.0.pdf
341134 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
